CN113040392A - Composite preparation containing ovalbumin peptide - Google Patents
Composite preparation containing ovalbumin peptide Download PDFInfo
- Publication number
- CN113040392A CN113040392A CN202110272057.7A CN202110272057A CN113040392A CN 113040392 A CN113040392 A CN 113040392A CN 202110272057 A CN202110272057 A CN 202110272057A CN 113040392 A CN113040392 A CN 113040392A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- composite
- powder
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 80
- 239000002131 composite material Substances 0.000 title claims abstract description 68
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 title claims abstract description 36
- 239000000843 powder Substances 0.000 claims abstract description 84
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 37
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 35
- 229940088594 vitamin Drugs 0.000 claims abstract description 34
- 229930003231 vitamin Natural products 0.000 claims abstract description 34
- 235000013343 vitamin Nutrition 0.000 claims abstract description 34
- 239000011782 vitamin Substances 0.000 claims abstract description 34
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 31
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 31
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 31
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims abstract description 22
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000010081 allicin Nutrition 0.000 claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 22
- 241001116389 Aloe Species 0.000 claims abstract description 21
- 240000004153 Hibiscus sabdariffa Species 0.000 claims abstract description 21
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 claims abstract description 21
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 21
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 21
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 20
- 229940013618 stevioside Drugs 0.000 claims abstract description 20
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000019202 steviosides Nutrition 0.000 claims abstract description 20
- 239000008223 sterile water Substances 0.000 claims abstract description 19
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 18
- 241000168525 Haematococcus Species 0.000 claims abstract description 15
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 15
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 15
- 241000195493 Cryptophyta Species 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 52
- 238000003756 stirring Methods 0.000 claims description 35
- -1 compound vitamin Chemical class 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 14
- 229930003756 Vitamin B7 Natural products 0.000 claims description 14
- 229930003316 Vitamin D Natural products 0.000 claims description 14
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 14
- 229930003448 Vitamin K Natural products 0.000 claims description 14
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 14
- 235000011912 vitamin B7 Nutrition 0.000 claims description 14
- 239000011735 vitamin B7 Substances 0.000 claims description 14
- 235000019166 vitamin D Nutrition 0.000 claims description 14
- 239000011710 vitamin D Substances 0.000 claims description 14
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 14
- 235000019168 vitamin K Nutrition 0.000 claims description 14
- 239000011712 vitamin K Substances 0.000 claims description 14
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 14
- 229940045997 vitamin a Drugs 0.000 claims description 14
- 229940046008 vitamin d Drugs 0.000 claims description 14
- 229940046010 vitamin k Drugs 0.000 claims description 14
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 13
- 244000017020 Ipomoea batatas Species 0.000 claims description 13
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 13
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 13
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 13
- 235000019155 vitamin A Nutrition 0.000 claims description 13
- 239000011719 vitamin A Substances 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 10
- 235000013312 flour Nutrition 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 241000168517 Haematococcus lacustris Species 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 229920001592 potato starch Polymers 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 3
- 240000006365 Vitis vinifera Species 0.000 claims description 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 240000008620 Fagopyrum esculentum Species 0.000 claims 2
- 235000004976 Solanum vernei Nutrition 0.000 claims 1
- 241000352057 Solanum vernei Species 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 25
- 230000036039 immunity Effects 0.000 abstract description 7
- 235000015097 nutrients Nutrition 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 4
- 235000019605 sweet taste sensations Nutrition 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 36
- 230000000052 comparative effect Effects 0.000 description 21
- 241000219051 Fagopyrum Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 230000013872 defecation Effects 0.000 description 10
- 206010010774 Constipation Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000976 ink Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 229960004192 diphenoxylate Drugs 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000002040 relaxant effect Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010016100 Faeces discoloured Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/27—Removal of unwanted matter, e.g. deodorisation or detoxification by chemical treatment, by adsorption or by absorption
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of protein application, and particularly relates to an ovalbumin peptide-containing composite preparation and a preparation method thereof. The composite preparation provided by the invention comprises the following components in parts by weight: 3-5 parts of ovalbumin peptide, 1-2 parts of haematococcus algae oligopeptide, 0.3-0.5 part of ginseng extract, 5-8 parts of grape seed extract, 2-3 parts of roselle extract, 1-2 parts of allicin, 0.5-1 part of aloe powder, 3-5 parts of stevioside, 1-1.5 parts of composite dietary fiber powder, 1-1.5 parts of composite vitamin and 20-30 parts of sterile water. The compound preparation provided by the invention can supplement various nutrient substances for human bodies, can help kill harmful bacteria and improve the immunity of the human bodies, has sweet taste, and is suitable for people of different ages.
Description
Technical Field
The invention belongs to the technical field of protein application, and particularly relates to an ovalbumin peptide-containing composite preparation and a preparation method thereof.
Background
Saccharides, lipids, proteins, vitamins, inorganic salts and water. In addition, dietary fiber is a seventh group of nutrients. They are converted into substances constituting the human body and energy for sustaining vital activities through metabolic processes together with oxygen that enters the human body through respiration. Therefore, they are essential elements for maintaining the material composition and physiological functions of the human body, and are also the material basis of life activities. Can be used for the normal demand and intake of human beings.
In recent years, with the continuous improvement of living standard of people, the demand of people for nutrition is increased day by day, various nutritional beverages, foods and medicines are innovated continuously, various products for supplementing nutrition are abundant aiming at different nutritional demands of human beings, however, while the related products of nutrition are increased continuously, people also need to learn to distinguish counterfeit and shoddy products, some developers add harmful components to human bodies when preparing nutritional products in order to save raw materials, and finally prepared finished products can provide nutrition for human bodies, but also bring harm to human health.
Based on this, chinese patent CN101496575B discloses a special nutritional food formula containing short peptides and probiotics, which uses food-borne short peptides as main raw materials, and adds various probiotics and functional oligosaccharides to form a composite formula, which can regulate intestinal function and prevent constipation and diarrhea, but when the probiotics is added, the compound is very easy to be mixed with other mixed bacteria, so that the human body is infected by germs, and even various diseases can be caused seriously.
Chinese patent CN104872679B discloses a health food for improving intestines and stomach and enhancing immunity function and a preparation method thereof, wherein a large amount of plant extracts, syrup, blueberry juice and other components are added into the food, and although the components can improve the digestive system of intestines and stomach and improve the immunity of human body, some of the components are obtained by artificial synthesis, and are easy to cause discomfort of human body and stimulate the body when mixed for use.
In conclusion, the nutriments in the prior art generally have the defects of easily stimulating the human body, easily being polluted by bacteria, causing diseases and the like.
Disclosure of Invention
Aiming at the defects generally existing in the prior art, the invention provides a compound preparation containing ovalbumin peptide and a preparation method thereof. The compound preparation provided by the invention can supplement various nutrient substances for human bodies, can help kill harmful bacteria and improve the immunity of the human bodies, has sweet taste, and is suitable for people of different ages.
In order to achieve the purpose, the invention adopts the technical scheme that:
a compound preparation containing ovalbumin peptide comprises the following components in parts by weight: 3-5 parts of ovalbumin peptide, 1-2 parts of haematococcus algae oligopeptide, 0.3-0.5 part of ginseng extract, 5-8 parts of grape seed extract, 2-3 parts of roselle extract, 1-2 parts of allicin, 0.5-1 part of aloe powder, 3-5 parts of stevioside, 1-1.5 parts of dietary fiber powder, 1-1.5 parts of compound vitamin and 20-30 parts of sterile water.
Preferably, the compound preparation comprises the following components in parts by weight: 4 parts of ovalbumin peptide, 1.5 parts of haematococcus oligomeric peptide, 0.4 part of ginseng extract, 7 parts of grape seed extract, 2.5 parts of roselle extract, 1.5 parts of allicin, 0.8 part of aloe powder, 4 parts of stevioside, 1.3 parts of composite dietary fiber powder, 1.2 parts of composite vitamin and 25 parts of sterile water.
Preferably, the composite dietary fiber powder is prepared from oat flour, buckwheat flour and purple sweet potato flour in a weight ratio of 2-3: 5-8: 7 to 9.
Preferably, the composite dietary fiber powder is prepared from oat flour, buckwheat flour and purple sweet potato flour in a weight ratio of 2.5: 6: 8.
Preferably, the vitamin complex comprises vitamin A, vitamin D, vitamin K and vitamin H in a weight ratio of 10-12: 6-8: 1-2: 2-3.
Preferably, the compound vitamin is prepared from vitamin A, vitamin D, vitamin K and vitamin H according to the weight ratio of 11: 7: 1.5: 2.5.
Preferably, the preparation method of the grape seed extract comprises the following steps: pulverizing grape seeds into powder by a pulverizer, adding 3 times of water by weight, setting the water temperature to 80 ℃, treating for 40min, separating an extracting solution, collecting the extracting solution, cooling to room temperature, filtering, passing the filtrate through a macroporous adsorption liquid resin column, eluting twice by pure water, eluting by 75% ethanol, collecting an eluent, reducing the temperature to 45 ℃, recovering the eluent under reduced pressure, and further spray-drying the concentrated solution.
The invention also provides a preparation method of the compound preparation, which comprises the following steps:
s1, heating the sterile water to 40-50 ℃, adding the composite dietary fiber powder, the composite vitamin and the aloe powder, and mixing and stirring uniformly to obtain a mixture I;
s2, cooling to 25-30 ℃, adding allicin, a roselle extract, a ginseng extract and a grape seed extract into the mixture I obtained in the step S1, and mixing and stirring uniformly to obtain a mixture II;
s3, keeping the temperature unchanged, adding the ovalbumin peptide and the haematococcus pluvialis oligopeptide into the mixture II obtained in the step S2, mixing and stirring uniformly, finally adding the stevioside into the mixture, mixing and stirring uniformly, cooling to room temperature, and storing.
Preferably, the mixing and stirring conditions in the step S1 are stirring at a rotating speed of 800-1000 rpm for 15-20 min; the mixing and stirring condition of the step S2 is stirring for 20-30 min at the rotating speed of 500-600 rpm; and the mixing and stirring condition of the step S3 is to stir for 50-60 min at the rotating speed of 300-500 rpm, so that the material is obtained.
The egg albumin peptide belongs to micromolecule oligomerization active polypeptide, is prepared by hydrolyzing egg albumin by adopting an enzyme method, can supplement protein and various trace elements for a human body, improves the immunity of the human body, reduces the probability of pathogenic bacteria infection, and meanwhile, the inventor discovers that the egg albumin peptide is supplemented with a small amount of haematococcus pluvialis oligopeptide in the preparation process of a composite preparation, can promote the peristalsis of small intestines, increases the digestion and absorption functions of the human body, and prevents constipation.
The ginseng extract, the grape seed extract and the roselle extract which are added in the invention are all pure natural extracts, so that various nutrient substances are supplemented for human bodies, no stimulation reaction is generated, moreover, the addition of the garlicin and the aloe powder prevents various bacteria from breeding in the preparation process, the sterile production of the compound preparation is ensured, and the addition of the compound dietary fiber and the compound vitamin can promote the digestion and absorption functions of intestinal tracts while enriching the nutrient components of the compound preparation.
Compared with the prior art, the compound preparation provided by the invention has the following advantages:
(1) the composite preparation provided by the invention is added with the small molecular oligopeptide, so that the immunity of a human body can be improved, the probability of pathogenic bacteria infection is reduced, and the guarantee is provided for the health of human;
(2) the compound preparation provided by the invention is added with various pure natural plant extracts, does not generate stimulation reaction on a human body, and supplements more nutrient substances for the human body;
(3) the allicin and the aloe powder added in the compound preparation provided by the invention have the sterilization function, so that the aseptic production of the compound preparation is ensured, and the preparation method provided by the invention has the advantages of simple process, no need of expensive reagents, equipment and the like, low production cost and high application value.
Detailed Description
The present invention is further explained with reference to the following specific examples, but it should be noted that the following examples are only illustrative of the present invention and should not be construed as limiting the present invention, and all technical solutions similar or equivalent to the present invention are within the scope of the present invention. The method and the device are operated according to the conventional technical method and the content of the instrument instruction, wherein the specific technology or condition is not indicated in the embodiment; the reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
The ovalbumin peptide, egg white albumin, is commercially available from Wuhan Rose science and technology Limited, CAS number: 9006-59-1; the Haematococcus oligopeptide is available from Haodde Biotechnology Ltd; the ginseng extract can be purchased from Shanxi Kepler Biotech limited; the roselle extract is available from sienna rain noro bioengineering ltd; the allicin can be purchased from Wuhan fresh Biotechnology Limited; the aloe powder may be purchased from Jiangsu Zhenya food Co., Ltd; the stevioside can be purchased from Zhengzhou Longhua chemical engineering food Co.
EXAMPLE 1A Complex preparation containing ovalbumin peptide
The compound preparation comprises the following components in parts by weight: 3 parts of ovalbumin peptide, 1 part of haematococcus oligopeptides, 0.3 part of ginseng extract, 5 parts of grape seed extract, 2 parts of roselle extract, 1 part of allicin, 0.5 part of aloe powder, 3 parts of stevioside, 1 part of dietary fiber powder, 1 part of compound vitamin and 20 parts of sterile water; the composite dietary fiber powder is prepared from oat powder, buckwheat powder and purple sweet potato powder in a weight ratio of 2: 5: 7, preparing a mixture; the compound vitamin is prepared from vitamin A, vitamin D, vitamin K and vitamin H according to the weight ratio of 10: 6: 1: 2, preparing a composition;
the preparation method of the grape seed extract comprises the following steps: pulverizing grape seeds into powder by a pulverizer, adding 3 times of water by weight, setting the water temperature to 80 ℃, treating for 40min, separating an extracting solution, collecting the extracting solution, cooling to room temperature, filtering, passing the filtrate through a macroporous adsorption liquid resin column, eluting twice by pure water, eluting by 75% ethanol, collecting an eluent, reducing the temperature to 45 ℃, recovering the eluent under reduced pressure, and further spray-drying the concentrated solution.
The preparation method of the compound preparation comprises the following steps:
s1, heating the sterile water to 40 ℃, adding the composite dietary fiber powder, the composite vitamin and the aloe powder, stirring at the rotating speed of 800rpm for 15min, and mixing and stirring uniformly to obtain a mixture I;
s2, cooling to 25 ℃, adding allicin, a roselle extract, a ginseng extract and a grape seed extract into the mixture I obtained in the step S1, stirring at 500rpm for 20min until the mixture is uniformly mixed and stirred to obtain a mixture II;
and S3, keeping the temperature unchanged, adding the ovalbumin peptide and the haematococcus pluvialis oligopeptide into the mixture II obtained in the step S2, stirring for 50min at the rotating speed of 300rpm, mixing and stirring uniformly, finally adding the stevioside into the mixture, stirring for 50min at the rotating speed of 300rpm until the mixture is mixed and stirred uniformly, reducing the temperature to the room temperature, and storing to obtain the tea drink.
Example 2A Complex preparation containing ovalbumin peptide
The compound preparation comprises the following components in parts by weight: 5 parts of ovalbumin peptide, 2 parts of haematococcus oligopeptides, 0.5 part of ginseng extract, 8 parts of grape seed extract, 3 parts of roselle extract, 2 parts of allicin, 1 part of aloe powder, 5 parts of stevioside, 1.5 parts of dietary fiber powder, 1.5 parts of vitamin complex and 30 parts of sterile water; the composite dietary fiber powder is prepared from oat powder, buckwheat powder and purple sweet potato powder in a weight ratio of 3: 8: 9 is prepared; the compound vitamin is prepared from vitamin A, vitamin D, vitamin K and vitamin H according to the weight ratio of 12: 8: 2: 3, preparing a composition; the grape seed extract was prepared in the same manner as in example 1.
The preparation method of the compound preparation comprises the following steps:
s1, heating sterile water to 50 ℃, adding the composite dietary fiber powder, the composite vitamin and the aloe powder, stirring at 1000rpm for 20min until the mixture is uniformly stirred to obtain a mixture I;
s2, cooling to 30 ℃, adding allicin, a roselle extract, a ginseng extract and a grape seed extract into the mixture I obtained in the step S1, stirring for 30min at the rotating speed of 600rpm until the mixture is uniformly mixed and stirred to obtain a mixture II;
and S3, keeping the temperature unchanged, adding the ovalbumin peptide and the haematococcus pluvialis oligopeptide into the mixture II obtained in the step S2, stirring at the rotating speed of 500rpm for 60min until the mixture is uniformly stirred, finally adding the stevioside into the mixture, stirring at the rotating speed of 500rpm for 60min until the mixture is uniformly stirred, reducing the temperature to the room temperature, and storing the mixture.
Example 3A Complex preparation containing ovalbumin peptide
The compound preparation comprises the following components in parts by weight: 4 parts of ovalbumin peptide, 1.5 parts of haematococcus oligomeric peptide, 0.4 part of ginseng extract, 7 parts of grape seed extract, 2.5 parts of roselle extract, 1.5 parts of allicin, 0.8 part of aloe powder, 4 parts of stevioside, 1.3 parts of composite dietary fiber powder, 1.2 parts of composite vitamin and 25 parts of sterile water; the composite dietary fiber powder is prepared from oat powder, buckwheat powder and purple sweet potato powder in a weight ratio of 2.5: 6: 8, preparing a mixture; the compound vitamin is prepared from vitamin A, vitamin D, vitamin K and vitamin H according to the weight ratio of 11: 7: 1.5: 2.5; the grape seed extract was prepared in the same manner as in example 1.
The preparation method of the compound preparation comprises the following steps:
s1, heating the sterile water to 45 ℃, adding the composite dietary fiber powder, the composite vitamin and the aloe powder, stirring at 900rpm for 18min, and mixing and stirring uniformly to obtain a mixture I;
s2, cooling to 27 ℃, adding allicin, a roselle extract, a ginseng extract and a grape seed extract into the mixture I obtained in the step S1, stirring at 550rpm for 25min until the mixture is uniformly mixed and stirred to obtain a mixture II;
and S3, keeping the temperature unchanged, adding the ovalbumin peptide and the haematococcus pluvialis oligopeptide into the mixture II obtained in the step S2, stirring at the rotating speed of 400rpm for 55min until the mixture is uniformly stirred, finally adding the stevioside into the mixture, stirring at the rotating speed of 400rpm for 55min until the mixture is uniformly stirred, reducing the temperature to the room temperature, and storing the mixture.
Comparative example 1A Complex preparation containing ovalbumin peptide
The compound preparation comprises the following components in parts by weight: 4 parts of ovalbumin peptide, 0.4 part of ginseng extract, 7 parts of grape seed extract, 2.5 parts of roselle extract, 1.5 parts of allicin, 0.8 part of aloe powder, 4 parts of stevioside, 1.3 parts of composite dietary fiber powder, 1.2 parts of composite vitamin and 25 parts of sterile water; the composite dietary fiber powder is prepared from oat powder, buckwheat powder and purple sweet potato powder in a weight ratio of 2.5: 6: 8, preparing a mixture; the compound vitamin is prepared from vitamin A, vitamin D, vitamin K and vitamin H according to the weight ratio of 11: 7: 1.5: 2.5; the grape seed extract was prepared in the same manner as in example 1.
The preparation method of the composite preparation is similar to that of example 3;
the difference from example 3 is that comparative example 1 does not contain haematococcus oligopeptides.
Comparative example 2A Complex preparation containing ovalbumin peptide
The compound preparation comprises the following components in parts by weight: 4 parts of ovalbumin peptide, 1.5 parts of haematococcus algae oligopeptide, 7 parts of grape seed extract, 2.5 parts of roselle extract, 1.5 parts of allicin, 0.8 part of aloe powder, 4 parts of stevioside, 1.3 parts of composite dietary fiber powder, 1.2 parts of composite vitamin and 25 parts of sterile water; the composite dietary fiber powder is prepared from oat powder, buckwheat powder and purple sweet potato powder in a weight ratio of 2.5: 6: 8, preparing a mixture; the compound vitamin is prepared from vitamin A, vitamin D, vitamin K and vitamin H according to the weight ratio of 11: 7: 1.5: 2.5; the grape seed extract was prepared in the same manner as in example 1.
The preparation method of the composite preparation is similar to that of example 3;
the difference from example 3 is that comparative example 2 does not contain ginseng extract.
Comparative example 3A Complex preparation containing ovalbumin peptide
The compound preparation comprises the following components in parts by weight: 4 parts of ovalbumin peptide, 1.5 parts of haematococcus oligomeric peptide, 0.4 part of ginseng extract, 7 parts of grape seed extract, 2.5 parts of roselle extract, 1.5 parts of allicin, 0.8 part of aloe powder, 4 parts of stevioside, 1.3 parts of composite dietary fiber powder, 1.2 parts of composite vitamin and 25 parts of sterile water; the composite dietary fiber powder is prepared from oat powder, buckwheat powder and purple sweet potato powder in a weight ratio of 1: 1: 1, preparing a composition; the compound vitamin is prepared from vitamin A, vitamin D, vitamin K and vitamin H according to the weight ratio of 11: 7: 1.5: 2.5; the grape seed extract was prepared in the same manner as in example 1.
The preparation method of the composite preparation is similar to that of example 3;
the difference from the example 3 is that the composite dietary fiber powder in the comparative example 3 is prepared by mixing oat flour, buckwheat flour and purple sweet potato flour according to the weight ratio of 1: 1: 1.
Comparative example 4A Complex preparation containing ovalbumin peptide
The compound preparation comprises the following components in parts by weight: 4 parts of ovalbumin peptide, 1.5 parts of haematococcus oligomeric peptide, 0.4 part of ginseng extract, 7 parts of grape seed extract, 2.5 parts of roselle extract, 1.5 parts of allicin, 0.8 part of aloe powder, 4 parts of stevioside, 1.3 parts of composite dietary fiber powder, 1.2 parts of composite vitamin and 25 parts of sterile water; the composite dietary fiber powder is prepared from oat powder, buckwheat powder and purple sweet potato powder in a weight ratio of 2.5: 6: 8, preparing a mixture; the compound vitamin is prepared from vitamin A, vitamin D, vitamin K and vitamin H according to the weight ratio of 1: 1: 1: 1, preparing a composition; the grape seed extract was prepared in the same manner as in example 1.
The preparation method of the composite preparation is similar to that of example 3;
the difference from example 3 is that the multivitamin of comparative example 4 is prepared by mixing vitamin a, vitamin D, vitamin K and vitamin H in a weight ratio of 1: 1: 1: 1.
Comparative example 5A Complex preparation containing ovalbumin peptide
The compound preparation comprises the following components in parts by weight: 4 parts of ovalbumin peptide, 1.5 parts of haematococcus oligomeric peptide, 0.4 part of ginseng extract, 7 parts of grape seed extract, 2.5 parts of roselle extract, 1.5 parts of allicin, 4 parts of stevioside, 1.3 parts of composite dietary fiber powder, 1.2 parts of composite vitamin and 25 parts of sterile water; the composite dietary fiber powder is prepared from oat powder, buckwheat powder and purple sweet potato powder in a weight ratio of 2.5: 6: 8, preparing a mixture; the compound vitamin is prepared from vitamin A, vitamin D, vitamin K and vitamin H according to the weight ratio of 11: 7: 1.5: 2.5; the grape seed extract was prepared in the same manner as in example 1.
The preparation method of the composite preparation is similar to that of example 3;
the difference from example 3 is that comparative example 5 does not contain allicin.
Comparative example 6A Complex preparation containing ovalbumin peptide
The compound preparation comprises the following components in parts by weight: 4 parts of ovalbumin peptide, 1.5 parts of haematococcus oligomeric peptide, 0.4 part of ginseng extract, 7 parts of grape seed extract, 2.5 parts of roselle extract, 1.5 parts of allicin, 0.8 part of aloe powder, 4 parts of stevioside, 1.3 parts of composite dietary fiber powder, 1.2 parts of composite vitamin and 25 parts of sterile water; the composite dietary fiber powder is prepared from oat powder, buckwheat powder and purple sweet potato powder in a weight ratio of 2.5: 6: 8, preparing a mixture; the compound vitamin is prepared from vitamin A, vitamin D, vitamin K and vitamin H according to the weight ratio of 11: 7: 1.5: 2.5; the grape seed extract was prepared in the same manner as in example 1.
The preparation method of the composite preparation is similar to that of example 3;
the difference from example 3 is that the temperature of the composite preparation in comparative example 6 was 25 ℃ at room temperature.
Test example 1 Sterilization test
1. Test samples: the composite preparations obtained in example 3 and comparative example 5 of the present invention;
2. test strains: escherichia coli, Staphylococcus, Vibrio cholerae;
3. the test method comprises the following steps: 20 sterile dried filter paper sheets are taken, 5 filter paper sheets are taken, the filter paper sheets are averagely divided into 4 groups, 15 mu L of each of the composite preparations prepared in the example 3 and the comparative example 5 is respectively dripped into each of the first group and the second group, the same amount of sterile purified water is dripped into the negative control group, the filter paper sheets are flatly placed in a clean sterile plate and dried in an incubator at 37 ℃ for standby.
Dipping with sterile cotton swab to 5 × 10 concentration6cfu/mL test bacterial suspension was evenly spread on the surface of nutrient agar medium plate for 3 times. The flat plate should rotate 60 degrees every time the cotton swab is smeared for 1 time, and finally the cotton swab is smeared for a circle around the edge of the flat plate; the plate was covered and dried at 25 ℃ for 5 min.
Sticking bacteriostatic agent sample pieces: each group of test patches was provided with 1 contamination plate, and each plate was provided with 5 test filter paper sheets and 2 negative control filter paper sheets, for a total of 7. A sample was taken with sterile forceps and placed on the surface of the plate. The distance between the centers of the various pieces is more than 25mm, and the distance between the centers of the various pieces and the periphery of the flat plate is more than 15 mm. After the sample is placed, the sample is lightly pressed by using sterile tweezers to be tightly attached to the surface of the flat plate. The plate is covered, the plate is placed in an incubator at 37 ℃, the culture is carried out for 16 to 18 hours, and the result is observed. The diameter of the antibacterial ring (including the patch) was measured with a vernier caliper and recorded.
Repeat the above experiment 3 times; when the inhibition zone is measured, the inhibition zone with uniform and complete aseptic growth should be selected. The diameter of the catheter is measured by taking the outer edge of the bacteriostatic ring as a boundary. The average of 3 measurements was taken as the final zone diameter.
4. And (3) test results: the specific test results are shown in table 1.
TABLE 1 bacteriostatic effect of different test samples
As can be seen from Table 1, the diameters of the inhibition zones of the negative control groups are all 0, so no inhibition zone is generated, while the diameters of the inhibition zones of the Escherichia coli of the group 3 of the invention are averagely 12.3mm, and the diameters of the inhibition zones of 3 times in the actual test process are all more than 10mm, while the diameters of the inhibition zones of the group of the comparative example 5 are obviously reduced after the garlicin is removed, which just proves that the sterilization effect is obvious although the addition amounts of the components are lower in the preparation process of the composite preparation.
Test example 2 Immunity-improving test
1. Test samples: the complex formulation of examples 1-3;
2. test subjects: total 120 SPF NIH female rats with body weight of 20 + -2 g are divided into 4 groups of 30 rats; the method comprises the following steps: before the test, each mouse is healthy and has no obvious adverse reaction;
3. the test method comprises the following steps: the MTT method is adopted for testing, the testing temperature is set to be 25 ℃, the relative humidity is set to be 60%, and the specific process is as follows: the low, medium and high doses are set according to 5-fold, 10-fold and 20-fold enlargement of the intake of 30mL/60kg (namely 0.5mL) of a human, 10 test animals are added in each dose, namely 2.5mL, 5mL and 10mL are added in the low, medium and high dose components respectively, and the equal amount of distilled water is directly used for intragastric administration in the negative control group.
After 30 days of continuous treatment, mice were sacrificed by cervical dislocation, and spleens were removed under aseptic conditions to prepare single cell suspensions (cell concentration 6X 10)6one/mL), adding the mouse splenocyte suspension into a 24-well culture plate respectively, wherein each processing well uses two multiple wells, each processing well is 1mL, 75 mu L of ConA is added into one well, the other well is added with distilled water with the same amount as the control, then the culture plate is placed in an incubator with 5% of CO2 and 37 ℃ for culture for 72h, 4h before the culture is finished, 50 mu L of MTT (5mg/mL) is added, the culture is continued till the end, then 1mL of DMSO is added into each well, the mixture is blown and evenly mixed to completely dissolve purple crystals, then the purple crystals are subpackaged into a 96-well culture plate, each well is subpackaged with 3 multiple wells, the value is measured at the wavelength of 570nm by a microplate reader, and the optical density value of the wells minus the optical density value of the wells is used for representing the proliferation capacity of lymphocytes. I.e., the proliferative capacity of lymphocytes ═ ConA well-control well OD values.
4. And (3) test results: see table 2 for specific test results.
TABLE 2 Effect of different test samples on the transforming ability of mouse lymphocytes
As shown in Table 2, compared with the negative control group, when the composite preparation prepared by the groups of examples 1 to 3 of the invention is adopted, the OD value of each dose group is higher than that of the negative control group and is increased along with the increase of the dose, and the calculation shows that the OD values of the low, medium and high dose groups in the groups of examples 1 to 3 of the invention have statistical significance (p is less than 0.05 or p is less than 0.01) compared with the control group, which can show that the composite preparation has the function of enhancing the lymphocyte transformation capability of mice and can enhance the immunity.
Test example 3 bowel relaxing test
1. Test samples: composite preparations prepared in examples 1 to 3 of the present invention and comparative examples 1 to 6;
2. test subjects: the total number of SPF-grade NIH female rats is 110, the body weight is 20 +/-2 g, the female rats are averagely divided into 11 groups, 10 female rats in each group are required to be fed normally before the test, and no adverse reaction is caused.
3. The test method comprises the following steps: the evaluation is carried out according to a laxative function detection method recorded in the technical Specification for health food inspection and evaluation, and the specific process is as follows: establishing a constipation model, orally intragastrically administering the molding drug compound diphenoxylate, establishing a mouse constipation model, intragastrically administering ink, and measuring the black defecation time of the first mouse grain and the defecation grain number and defecation weight in 5 hours to reflect the defecation condition of the mouse.
After the constipation model is successfully established, the mice of each group are respectively gazed with 10mL of the test sample, the gazed is carried out for 2 times every day, the control group is gazed with physiological saline with the same amount every day, after the continuous treatment for 7 days, the mice of each group are fasted for 16 hours without water prohibition, the blank control group is given with distilled water with the same amount, then the experiment group and the negative control group are respectively given with compound diphenoxylate, after half an hour, the mice of each group are gazed with Chinese ink, the animals are all fed in a single cage, the animals are fed with normal drinking water and food, the black stool discharging time of the first grain of each mouse is recorded from the Chinese ink filling, and the number and the weight of the black stool discharging grains within 5 hours.
4. And (3) test results: the specific test results are shown in Table 3.
TABLE 3 defecation results in groups of mice
As can be seen from table 3 above, the composite preparation prepared in the examples 1 to 3 of the present invention has a good effect of relaxing bowel, and can effectively treat constipation, and the comparative example group destroys the synergistic effect among the components of the present invention, which results in a great reduction in the effect of relaxing bowel, especially the effects of the comparative example 1 and the comparative examples 3 to 4 are significantly reduced.
Finally, it should be noted that the above-described embodiments are described to facilitate understanding and use of the invention by those of ordinary skill in the art. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.
Test example 2 animal test of health food for relaxing bowel
The oral liquids prepared in example 10, example 13, comparative example 3 and comparative example 4 were evaluated according to the method for testing the bowel relaxing function in "test and evaluation of health food" as follows:
1. the test method comprises the following steps:
1.1 selecting adult female mice with the weight of 18-22 g for experimental animals, and 10 animals in each group; the method comprises the steps of orally intragastrically administering the modeling drug compound diphenoxylate, establishing a constipation model of a mouse, intragastrically administering ink, and measuring the first defecation time, the number of defecation grains in 5 hours and the defecation weight of the mouse to reflect the defecation condition of the model mouse.
1.2 packet case:
group 1: gavage the oral liquid of example 10:
group 2: gavage the oral liquid of example 13:
group 3: gavage the oral liquid of control example 3;
group 4: gavage the oral liquid of control example 4;
the mice of the above group are taken twice a day, 10ml each time, and are taken after being diluted by warm boiled water;
group 5: the model control group is perfused with physiological saline with the same amount as the gastric lavage group;
group 6: the control group was perfused with the same amount of normal saline.
1.3 model building
After 7 days of the test samples, the mice in each group were fasted for 16 hours.
The blank control group of group 6 was given distilled water, and the groups 1-6 were given compound diphenoxylate by gavage.
1.4 specific method of index measurement
After the group 1-5 is given the compound diphenoxylate for 0.5 hour, the group 1-6 is given the mice to drench with the ink, the animals are all raised in a single cage, the animals normally drink water for eating, the first time of discharging the black feces of each mouse is recorded from the ink drenching, and the number and the weight of the discharged black feces are recorded within 5 hours.
2. And (3) test results:
the specific results are shown in Table 2.
TABLE 2 results of defecation in groups of mice
Finally, it should be noted that the above-described embodiments are described to facilitate understanding and use of the invention by those of ordinary skill in the art. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.
Claims (9)
1. The compound preparation containing the ovalbumin peptide is characterized by comprising the following components in parts by weight: 3-5 parts of ovalbumin peptide, 1-2 parts of haematococcus algae oligopeptide, 0.3-0.5 part of ginseng extract, 5-8 parts of grape seed extract, 2-3 parts of roselle extract, 1-2 parts of allicin, 0.5-1 part of aloe powder, 3-5 parts of stevioside, 1-1.5 parts of dietary fiber powder, 1-1.5 parts of compound vitamin and 20-30 parts of sterile water.
2. The composite preparation of claim 1, comprising the following components in parts by weight: 4 parts of ovalbumin peptide, 1.5 parts of haematococcus oligomeric peptide, 0.4 part of ginseng extract, 7 parts of grape seed extract, 2.5 parts of roselle extract, 1.5 parts of allicin, 0.8 part of aloe powder, 4 parts of stevioside, 1.3 parts of composite dietary fiber powder, 1.2 parts of composite vitamin and 25 parts of sterile water.
3. The compound preparation as claimed in claim 1 or 2, wherein the compound dietary fiber powder is prepared from oat flour, buckwheat flour and purple sweet potato flour in a weight ratio of 2-3: 5-8: 7 to 9.
4. The composite preparation as claimed in claim 3, wherein the composite dietary fiber powder is prepared from oat flour, buckwheat flour and purple potato flour in a weight ratio of 2.5: 6: 8.
5. The complex preparation as claimed in claim 1 or 2, wherein the complex vitamin is prepared from vitamin A, vitamin D, vitamin K and vitamin H in a weight ratio of 10-12: 6-8: 1-2: 2-3.
6. The complex preparation of claim 5, wherein the complex vitamins are prepared from vitamin A, vitamin D, vitamin K and vitamin H in a weight ratio of 11: 7: 1.5: 2.5.
7. The complex formulation of claim 1, wherein the grape seed extract is prepared by a method comprising: pulverizing grape seeds into powder by a pulverizer, adding 3 times of water by weight, setting the water temperature to 80 ℃, treating for 40min, separating an extracting solution, collecting the extracting solution, cooling to room temperature, filtering, passing the filtrate through a macroporous adsorption liquid resin column, eluting twice by pure water, eluting by 75% ethanol, collecting an eluent, reducing the temperature to 45 ℃, recovering the eluent under reduced pressure, and further spray-drying the concentrated solution.
8. A method for preparing the composite formulation of any one of claims 1 to 7, comprising the steps of:
s1, heating the sterile water to 40-50 ℃, adding the composite dietary fiber powder, the composite vitamin and the aloe powder, and mixing and stirring uniformly to obtain a mixture I;
s2, cooling to 25-30 ℃, adding allicin, a roselle extract, a ginseng extract and a grape seed extract into the mixture I obtained in the step S1, and mixing and stirring uniformly to obtain a mixture II;
s3, keeping the temperature unchanged, adding the ovalbumin peptide and the haematococcus pluvialis oligopeptide into the mixture II obtained in the step S2, mixing and stirring uniformly, finally adding the stevioside into the mixture, mixing and stirring uniformly, cooling to room temperature, and storing.
9. The method according to claim 8, wherein the mixing and stirring conditions in step S1 are stirring at 800-1000 rpm for 15-20 min; the mixing and stirring condition of the step S2 is stirring for 20-30 min at the rotating speed of 500-600 rpm; and the mixing and stirring condition of the step S3 is to stir for 50-60 min at the rotating speed of 300-500 rpm, so that the material is obtained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110272057.7A CN113040392A (en) | 2021-03-12 | 2021-03-12 | Composite preparation containing ovalbumin peptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110272057.7A CN113040392A (en) | 2021-03-12 | 2021-03-12 | Composite preparation containing ovalbumin peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113040392A true CN113040392A (en) | 2021-06-29 |
Family
ID=76512415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110272057.7A Pending CN113040392A (en) | 2021-03-12 | 2021-03-12 | Composite preparation containing ovalbumin peptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113040392A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115024496A (en) * | 2022-06-21 | 2022-09-09 | 南京立康生物科技有限公司 | Composite preparation containing ovalbumin peptide |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101524446A (en) * | 2008-03-07 | 2009-09-09 | 湖南泰尔制药股份有限公司 | Process for preparing grape seed extract |
| CN103284042A (en) * | 2013-06-03 | 2013-09-11 | 吉林大学 | Egg-white protein peptide containing enteral nutrition preparation and preparation method thereof |
| CN105876440A (en) * | 2015-01-08 | 2016-08-24 | 无锡索莱美生物科技有限公司 | Short-peptide containing compound special nutritional food recipe |
| CN107518413A (en) * | 2017-08-15 | 2017-12-29 | 北京盈泰正和生物科技有限公司 | A kind of oligomeric peptide combinations of the albumen of strengthen immunity and preparation method thereof |
| CN108157728A (en) * | 2017-12-18 | 2018-06-15 | 沈阳润东生物科技有限公司 | A kind of breast peptide multielement protein solid beverage |
| CN109170469A (en) * | 2018-09-30 | 2019-01-11 | 四川威多信科技有限公司 | A kind of Isin glue collagen peptide solid beverage and preparation method thereof |
-
2021
- 2021-03-12 CN CN202110272057.7A patent/CN113040392A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101524446A (en) * | 2008-03-07 | 2009-09-09 | 湖南泰尔制药股份有限公司 | Process for preparing grape seed extract |
| CN103284042A (en) * | 2013-06-03 | 2013-09-11 | 吉林大学 | Egg-white protein peptide containing enteral nutrition preparation and preparation method thereof |
| CN105876440A (en) * | 2015-01-08 | 2016-08-24 | 无锡索莱美生物科技有限公司 | Short-peptide containing compound special nutritional food recipe |
| CN107518413A (en) * | 2017-08-15 | 2017-12-29 | 北京盈泰正和生物科技有限公司 | A kind of oligomeric peptide combinations of the albumen of strengthen immunity and preparation method thereof |
| CN108157728A (en) * | 2017-12-18 | 2018-06-15 | 沈阳润东生物科技有限公司 | A kind of breast peptide multielement protein solid beverage |
| CN109170469A (en) * | 2018-09-30 | 2019-01-11 | 四川威多信科技有限公司 | A kind of Isin glue collagen peptide solid beverage and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115024496A (en) * | 2022-06-21 | 2022-09-09 | 南京立康生物科技有限公司 | Composite preparation containing ovalbumin peptide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105231444A (en) | Meal replacement combined enzyme and preparation method thereof | |
| CN110301629A (en) | A kind of full nutrient solid beverage of tumor patient and preparation method thereof | |
| CN109757733A (en) | A kind of oral polypeptide powder and its preparation method and application | |
| WO2017003206A1 (en) | Method for producing raw pills of fermented minerals having functions of improving constipation and recovery from fatigue, and raw pills of fermented minerals produced thereby | |
| CN110432482A (en) | A kind of infant allergic dermatitis tailored version clinical nutrition formula and preparation method thereof | |
| CN111329055B (en) | Preparation method of trifoliate acanthopanax enzyme | |
| CN115838676A (en) | Traditional Chinese medicine fermentation by using novel lactobacillus plantarum strain and application | |
| CN114916584A (en) | Solid beverage for inhibiting activity of helicobacter pylori | |
| CN113040392A (en) | Composite preparation containing ovalbumin peptide | |
| CN112385843A (en) | Balanced nutrition powder containing composite prebiotics and preparation method thereof | |
| CN110547447A (en) | Royal jelly collagen fruit enzyme and preparation method thereof | |
| WO2012024817A1 (en) | Whole egg protein peptides, preparation method and use thereof | |
| CN1840011A (en) | Chinese medicine for treating prostate disease | |
| CN110074189A (en) | A kind of infant's diatery supplement and preparation method thereof adding human milk oligosaccharides | |
| KR102244732B1 (en) | Probiotic acetic acid bacteria Acetobacter pasteurianus MGLV and its immunomodulatory effect | |
| CN112704234A (en) | Nutritional composition containing composite peptide and probiotics and preparation method thereof | |
| CN102475275A (en) | Long-life medlar powder | |
| RU2538116C2 (en) | Acellular probiotic based biologically active complex, fodder composition containing such complex, method for farm animals and poultry feeding | |
| CN112042846A (en) | Sea-buckthorn solid beverage for enhancing immunity and inhibiting tumors and preparation method thereof | |
| CN111067108A (en) | Rose tartary buckwheat polypeptide oral liquid and preparation method thereof | |
| RU2341276C1 (en) | Method of gastrointestinal disturbance prevention in newborn calfs | |
| WO2021071375A1 (en) | Functional drinking water | |
| JP2005097133A (en) | IgA PRODUCTION PROMOTER DERIVED FROM SPARASSIS CRISPA | |
| CN106722970A (en) | A kind of compound fruit enzyme and preparation method thereof | |
| CN114431361B (en) | Chicken feed for improving laying rate and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210629 |